Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10181868 | 1.00 | HSD17B10 (0.37) | HSD17B10ALDH1A1KDM4EHPGDADRA1A | |
| SCHEMBL14724993 | 0.91 | LMNA (0.33) | HSD17B10POLBTLR7 | |
| SCHEMBL6984567 | 0.85 | ALDH1A1 (0.39) | HSD17B10ALDH1A1KDM4EHPGDADRA1A | |
| SCHEMBL10183264 | 0.85 | ALDH1A1 (0.39) | HSD17B10ALDH1A1KDM4EHPGDADRA1A | |
| SCHEMBL10181491 | 0.79 | POLB (0.40) | HSD17B10ALDH1A1POLBTLR7ADRB2 | |
| SCHEMBL18948300 | 0.73 | KDM4E (0.42) | HSD17B10ALDH1A1KDM4EHPGDADRA1A | |
| SCHEMBL14725022 | 0.71 | KDM4E (0.31) | HSD17B10ALDH1A1KDM4EHPGDADRA1A | |
| SCHEMBL6983873 | 0.69 | ALDH1A1 (0.33) | HSD17B10ALDH1A1KDM4EHPGDADRA1A | |
| SCHEMBL6985619 | 0.69 | ALDH1A1 (0.46) | HSD17B10ALDH1A1POLBADRB2ADRB1 | |
| SCHEMBL10181949 | 0.68 | ALDH1A1 (0.44) | HSD17B10ALDH1A1POLBADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120121541-A1 | 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121541-A1 | 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | TLR5, THPO, IDO1 | HSD17B10 2583/4885ALDH1A1 340/4885KDM4E 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.